NEWS AND EVENTS
RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2017 (GLOBE NEWSWIRE)
Metabolon announced today that it has partnered with Israeli precision medicine firm InnVentis to study metabolomics in individuals with chronic inflammatory diseases such as rheumatoid arthritis. The deal joins Metabolon's metabolomics expertise with InnVentis' big data and machine learning platform, the company said. Specific terms of the partnership were not disclosed. "Our goal is to use our proprietary technology in conjunction with InnVentis' platform to provide a more accurate health assessment of patients, as well as clinically useful information," Metabolon CEO John Ryals said in a statement. "Metabolomics may help answer key biological questions about these complex disorders and improve personalized treatment." InnVentis CEO Thomas Wilckens added that his company is aiming to use metabolomics and other omics technologies "to enable novel, real-time disease management for clinicians and patients.. This will include drug responder identification upon first diagnosis, as well as drug dosing management."
Chronic inflammation is a leading risk and driver in virtually every chronic disease
The key to successful treatment is precise diagnosis and treatment optimization
An underserved billion dollar market
A disruptive approach
The right intervention and treatment, at the right time
will be boosted furtherby studies using multiple omics platforms.
By embracing big data and integrating host genetics with longitudinal [...] data,
the extent to which [...] any particular factors are associated
with disease may become apparent.
Nature Medicine Special Issue on Inflammation, July 2015